| abstract |
The present invention relates to α1a and/or α1d adrenergic receptor antagonists. Compounds provided herein can function as α1a and/or α1d adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through α1a and/or α1d adrenergic receptor. Compounds provided herein can be used for the treatment of benign prostatic hyperplasia (BPH) and the related symptoms thereof, lower urinary tract symptoms (LUTS) associated with or without BPH. Processes for the preparation of the provided compounds, as well as, pharmaceutical composition containing the provided compounds, and methods of treating benign prostatic hyperplasia or related symptoms thereof are provided herein. |